Merck KGaA - Articles and news items

bioreactors

Bioreactors and Fermenters market to reach US$ 4461 million by 2024

Industry news / 11 May 2017 / Niamh Marriott, Junior Editor

The global Bioreactors and Fermenters Market features a largely consolidated vendor landscape and a low to moderate level of competition, says a new report

Fertile ground: Why Merck is investing in fertility treatment centres

Blog, Z Homepage promo / 1 March 2017 / Dorothea Wenzel, Senior VP Global Business Franchise Fertility, Merck

We caught up with Merck’s Dorothea Wenzel to hear all about the latest in fertility treatments, training and technologies and the truth about infertility…

Phase III trial to evaluate avelumab as first-line treatment in ovarian cancer

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer…

Immunotherapy shrinks tumours in neuroblastoma patients

Industry news / 3 June 2016 / Victoria White, Digital Content Producer

Neuroblastoma tumours shrank in 80% of young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody…

Trial to investigate avelumab and entinostat in ovarian cancer

Industry news / 4 January 2016 / Victoria White

Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells…

Merck KGaA and Pfizer advance avelumab clinical development programme

Industry news / 22 December 2015 /

Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer…

Evofosfamide fails in two late-stage cancer trials

Industry news / 7 December 2015 / Victoria White

Merck KGaA will also not be pursuing the treatment in pancreatic adenocarcinoma after the drug failed in two late-stage clinical trials…

COMP issues positive opinion for ODD for avelumab in MCC

Industry news / 1 December 2015 / Victoria White

An official decision on the Ophran Drug Designation is expected from the European Commission in December…

FDA grants Breakthrough Therapy designation to avelumab for MCC

Industry news / 18 November 2015 / Victoria White

Avelumab (MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody…

Phase III study of avelumab in NSCLC starts

Industry news / 4 November 2015 / Victoria White

Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer…

FDA grants Fast Track designation to avelumab for Merkel cell carcinoma

Industry news / 8 October 2015 / Victoria White

The designation relates to the clinical development programme for avelumab in metastatic MCC, which includes the Phase II study, JAVELIN Merkel 200…

FDA Fast Track designation for evofosfamide for treatment of patients living with advanced pancreatic cancer

Industry news / 12 May 2015 / Victoria White

The FDA has granted Fast Track designation for the development of evofosfamide for the treatment of patients with advanced pancreatic cancer…

  • Page 1 of 2
  • 1
  • 2
  • >

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+